Sage Therapeutics Stock Forecast, Price & News

Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

Is Sage Therapeutics a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics or view top-rated stocks.

How has Sage Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have decreased by 11.3% and is now trading at $37.51.
View which stocks have been most impacted by COVID-19.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Sage Therapeutics.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($1.84) by $0.37. Sage Therapeutics had a negative trailing twelve-month return on equity of 23.76% and a net margin of 57.61%. During the same period last year, the firm posted ($2.03) earnings per share.
View Sage Therapeutics' earnings history.

What price target have analysts set for SAGE?

17 brokers have issued twelve-month price targets for Sage Therapeutics' shares. Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next year. This suggests a possible upside of 88.3% from the stock's current price.
View analysts' price targets for Sage Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:

• Barry E. Greene, President, Chief Executive Officer & Director (LinkedIn Profile)
• Kimi E. Iguchi, Chief Financial Officer & Treasurer
• Al Robichaud, Chief Scientific Officer
• Jim Doherty, Chief Research Officer
• Amy Schacterle, Senior VP-Research & Development Strategy

Who are some of Sage Therapeutics' key competitors?

Some companies that are related to Sage Therapeutics include United Therapeutics (UTHR), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), CureVac (CVAC), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR), Grifols (GRFS), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Zai Lab (ZLAB), BridgeBio Pharma (BBIO) and Blueprint Medicines (BPMC).
View all of SAGE's competitors.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (11.49%), Bellevue Group AG (5.45%), BlackRock Inc. (4.88%), Janus Henderson Group PLC (1.78%), Geode Capital Management LLC (1.49%) and Point72 Asset Management L.P. (1.29%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Barry E Greene, Barry E Greene, James M Frates and Jeffrey M Jonas.
View institutional ownership trends for Sage Therapeutics.

Which major investors are selling Sage Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Invesco Ltd., Jane Street Group LLC, Caption Management LLC, Morgan Stanley, Citadel Advisors LLC, Two Sigma Advisers LP, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Sage Therapeutics or view top insider-selling stocks.

Which major investors are buying Sage Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bellevue Group AG, Point72 Asset Management L.P., Asymmetry Capital Management L.P., The Manufacturers Life Insurance Company , Geode Capital Management LLC, Pinnacle Associates Ltd., and Integral Health Asset Management LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $37.51.

How much money does Sage Therapeutics make?

Sage Therapeutics has a market capitalization of $2.21 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or $12.51 on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 298 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is www.sagerx.com.

Where are Sage Therapeutics' headquarters?

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at [email protected], or via fax at 617-299-8379.